<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Polymorphic acetylation was investigated in twenty-seven patients with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> using the sulphadimidine test </plain></SENT>
<SENT sid="1" pm="."><plain>Whereas the finding of 51% slow acetylators in seventy-eight control persons agreed well with the expected frequency in a continental European population, the prevalence of slow acetylators in <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> was increased to 78% (P less than 0.03, Woolf's G-test) </plain></SENT>
<SENT sid="2" pm="."><plain>After oral administration of <z:chebi fb="32" ids="36927">14C</z:chebi>-<z:chebi fb="0" ids="160246">aminopyrine</z:chebi> there was no significant difference between seventeen patients with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> and twenty-seven <z:mpath ids='MPATH_458'>normal</z:mpath> controls in total plasma clearance of <z:chebi fb="0" ids="160246">aminopyrine</z:chebi> (280 +/- SD 100 and 270 +/- 60 ml/min) and in the disappearance curve of 14CO2 in breath (0.23 +/- 0.04 and 0.22 +/- 0.03 h-1, respectively) </plain></SENT>
<SENT sid="3" pm="."><plain>Thus, whereas <z:chebi fb="0" ids="160246">aminopyrine</z:chebi> metabolism appears unaffected in the examined patients, the data documents a new association between slow acetylator status and <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> </plain></SENT>
</text></document>